MADARA: Q1 Turnover Update

A boost in e-commerce sales is driving turnover growth

MADARA Cosmetics ('MADARA' or the 'Company'), a leading Latvian producer of natural beauty products, is listed on Nasdaq Baltic First North and reports a full set of financial performance numbers semi-annually. However, the Company reported its consolidated unaudited turnover for Q1 2021, on 27th April 2021, at EUR 4.48m (+38.7% y-o-y, +12% q-o-q). This growth is primarily driven by a significant increase in direct e-commerce sales. The share of direct e-commerce in the Company's turnover increased to 45% (+14pp y-o-y, +11pp q-o-q) in Q1. During the past couple of years, MA-DARA made substantial investments into developments of e-commerce channels, and these investments have started to pay off. The customer's interaction and experience through the use of diagnostic tools and digital apps, as well as electronic payments and delivery, are transforming rapidly. In the case of e-commerce sales, retailers must continue to invest in an Omni-channel presence. Omni-channel bundles include retail stores, online stores, mobile stores, mobile app stores as well as other methods of engaging with a customer. Several communication channel options give the customer the ability to be in constant contact with the retailer through multiple means at the same time. We believe that a company like MADARA, which is persistently focusing on its Omni-channel presence, would benefit from this trend.

The global market for natural and organic personal care products is continuing to experience a positive trajectory. Although the COVID-19 pandemic softened growth rates, consumer demand for natural and organic products remains strong. Due to the temporary closures of the brick and mortar stores, the COVID-19 pandemic resulted in supply chain delays, ultimately having a detrimental effect on cosmetics and personal care goods, including organic products. However, the outbreak of the pandemic has contributed to evolving market tastes, and people are proactively searching for natural and organic products, which in turn is projected to drive the growth at a faster pace. Key players are counting on the e-commerce channels in order to improve sales of their cosmetics and personal care goods, which could emerge as the principal channel even after the pandemic ends.

The Company continues to generate over 90% of its revenues from EU countries, with 63% of Q1 turnover being generated in the EU countries (excluding Latvia), 29% in Latvia, and 8% outside the EU. In Q1, turnover in the EU countries (excluding Latvia) and Latvia grew 40% y-o-y and 24% y-o-y, respectively, while the turnover outside the European Union increased by 133% y-o-y.

The Company is actively developing new products and launched two lip balms, several body and face care products, such as vitamin C face cream, at the beginning of the year. Further, due to the high demand and customer satisfaction of the Company's sunscreen products, the development of SPF50 sunscreens was finalised in spring, and these will be available for sale very soon.

| Key Numbers (EURm) | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E |
|-------------------------|------|------|------|------|----------------|--------|
| Sales (EURm) | 7.4 | 9.5 | 11.5 | 16.1 | Under review | |
| Sales growth (%) | 26.3 | 28.7 | 21.2 | 39.3 | | |
| Net profit (EURm) | 1.2 | 1.5 | 1.6 | 3.4 | | |
| EPS (EUR) | 0.33 | 0.40 | 0.42 | 0.91 | | |
| P/E (x) | 22.5 | 19.6 | 18.8 | 21.8 | | |
| Payout per share (EUR)# | 0.05 | 0.09 | 0.12 | 0.15 | | roviow |
| Payout yield (%) | 0.7 | 1.1 | 1.5 | 0.8 | Officer review | |
| P/B (x) | 3.9 | 3.5 | 3.1 | 6.0 | | |
| EV/Sales (x) | 3.2 | 2.7 | 2.4 | 4.5 | | |
| EV/EBITDA (x) | 13.5 | 13.0 | 12.5 | 17.2 | | |
| EV/EBIT (x) | 17.7 | 17.6 | 18.4 | 20.6 | | |
| ROE (%) | 24.6 | 19.3 | 17.4 | 31.2 | | |

Source: MDARA

| Comp | any P | rofile |
|------|-------|--------|
|------|-------|--------|

| Listing Market: | First North Baltic Share List |
|-------------------|-------------------------------|
| Bloomberg Ticker: | MDARA LR |
| ISIN: | LV0000101624 |
| Industry: | Consumer Goods |
| Sector: | Personal & Household Goods |
| No. of Employees: | 148 |
| Website: | www.madaracosmetics.com |

Share Data, as of 26th Apr 2021

| Current Share Price (EUR): | 21.40 |
|------------------------------------|------------|
| Fair Value Range (FVR), EUR: | U.R. |
| Downside, % (to mid-point of FVR): | n.a. |
| 52-week High/Low (EUR): | 23.00/7.50 |
| 3m Avg. Daily Volume (th): | 0.26 |
| Market Cap (EURm): | 80.66 |
| Ordinary Shares (m): | 3.77 |

Key Shareholders, as of 9th Feb 2021

| - | |
|-------------------------|--------|
| Uldis Iltners | 23.93% |
| Lote Tisenkopfa-Iltnere | 23.77% |
| Oy Transmeri Group AB | 22.94% |
| Liene Drāzniece | 6.79% |
| Zane Tamane | 6.67% |

12-Month Price Performance



LHV Fair Value Range:

Under review*



^{*}Payout per share include dividends and share capital reduction.

^{*} Effective from 22nd Dec 2020

27th April 2021 **Baltic Insight**

The Company reiterated its target, initially announced in December 2020, to achieve revenues of EUR 27m in 2023. The Company is planning to achieve this target by doubling its production compared to the 2020 level. At the end of last year, work began on preparing the Company for doubling its production capacity. The Company is targeting to improve its organisation, production, and logistics processes, as well as to supplement the technological equipment of production in the existing plant. According to the management, by improving the above-mentioned aspects, the Company will be able to ensure the doubling of the production volume in the existing premises, and the capital investments will not significantly exceed the level of previous years. Given the favourable market trend for the Company's natural and organic product offerings, a growing portion of e-commerce sales in revenues, increasing recognition of MADARA brands, new innovative product launches using significant in-house R&D activities, ongoing and future penetration in key markets, and growth potential of organic and natural cosmetics industry in general, we believe the Company can meet this guidance.

Due to the recent developments in the Company's business, we are in the process of revising our projections as well as the fair value



Baltic Review 27th April 2021

Contacts:

Ivars BergmanisSander DanilHead of Institutional MarketsSenior AnalystTel: +372 680 2720Tel: +372 680 2793Mob: +372 534 11114sander.danil@lhv.ee

ivars.bergmanis@lhv.ee

Date and time of sign-off: Tuesday 27th April 18:00

Disclaimer

The copyright in this report belongs to AS LHV Pank (hereinafter 'LHV'). LHV is a full service bank with a focus on the Baltic region. LHV is a member of the Tallinn, Riga, and Vilnius stock exchanges. LHV is under the supervision of the Estonian Financial Supervisory Authority (Finantsinspektsioon; see also www.fi.ee).

Readers of this report should be aware of that LHV and LHV affiliated companies (hereinafter 'LHV's Group') are constantly seeking to offer investment banking services to companies (hereinafter, 'Company' or 'Companies') mentioned in research reports or may have other financial interests in those Companies.

AS LHV Pank has made an arrangement with AUGA group ('AUGA'), AB whereby LHV's research analysts independently produce research reports on AUGA group and provide them to AUGA for the purposes of providing more information about AUGA to investors who are not customers of LHV. In October 2019, AUGA group selected AS LHV Pank as an advisor as well as arranger and manager for a bond programme. The first tranche of such bonds were issued at the end of 2019.

AS LHV Pank has made an agreement with EfTEN Real Estate Fund III on commercial terms whereby LHV's research analysts independently produce research reports on EfTEN Real Estate Fund III. In turn, LHV is paid a fixed fee for a certain number of reports on an annual basis.

AS LHV Pank has made an arrangement with MADARA Cosmetics ('MADARA'), whereby LHV's research analysts independently produce research reports on MADARA and provide them to MADARA for the purposes of providing more information about MADARA to investors who are not customers of LHV. MADARA is listed on the NASDAQ Baltic First North List. In addition to being the certified adviser for MADARA, LHV is also the certified adviser for Linda Nektar ('LINDA') on NASDAQ Baltic First North on an ongoing fee-based arrangement

LHV's Group acts as a market maker /(and)/ liquidity provider for TKM1T, APG1L, TVEAT, OLF1R, HMX1R, LINDA, and MDARA.

All reports are produced by LHV's research department. In order to proactively prevent conflicts of interest, LHV has established several procedural and physical measures. Such measures include, among other things, confidentiality measures through separation, or so-called "Chinese walls", virtual and physical barriers to limit the exchange of information between different departments, groups or individuals within LHV Group. These measures are monitored by the compliance department of LHV. LHV does everything possible to avoid the conflict of interests but it cannot guarantee that conflict of interests situations do not arise at all.

LHV provides coverage on this company on a regular basis, therefore this report may include assumptions and findings laid out in greater detail elsewhere. If interested, clients may approach LHV for these previous reports.

This report is based upon information available to the general public. The information contained within has been compiled from sources deemed to be suitably reliable. However, no guarantee to that effect is given and henceforth neither the accuracy, completeness, nor the timeliness of this information should be relied upon. Any opinions expressed herein reflect a professional judgment of market conditions as at the date of publication of this document and are therefore subject to change without prior notice.

LHV reviews its estimates at least once during financial reporting period and upon most major financial events.

The report is not intended for public distribution and may not be reproduced, redistributed or published in any form whatsoever (in whole or in part) without prior written permission of LHV. The user shall be liable for any non-authorised reproduction or use of this report, whether in whole or in part, and such, reproduction may lead to legal proceedings. LHV does not accept any liability whatsoever for the actions of third parties in this respect. This information may not be used to create any financial instruments or products or any indices.



Baltic Review 27th April 2021

Neither LHV nor its directors nor its representatives nor its employees will accept liability for any injuries, losses or damages, direct or consequential caused to the reader that may result from the reader's acting upon or using the content contained in the publication.

The analyst(s) of this report hereby confirm that the views expressed in this report accurately reflect their personal views about the Companies and securities covered at the time of publication. The authors further confirm that they have not been, nor are nor will be receiving direct or indirect compensation in exchange for expressing any of the views contained in the report.

The analysts receive remuneration based on among others, the overall group revenues of LHV, including investment banking revenues. However, no compensation is based on a specific investment banking transaction. Trading with securities which are covered by a report is subject to strict compliance with internal rules governing own-account trading by staff members and third parties acting for the account of such staff members.

This research report is produced for the private information of recipients and LHV is not advising nor soliciting any action based upon it. If you are not a client of LHV, you are not entitled to this research report.

This report does not by any means constitute an offer or a solicitation, nor a recommendation to purchase or sell securities, commodities, currencies or other investments referred to herein.

This report does not constitute independent investment advice. LHV does not assume any fiduciary responsibility or liability for any consequence, financial or otherwise, arising from any investment or disinvestment decision taken on the basis of this report. It has been prepared without regard to the individual financial circumstances and objectives of those who receive this report. The securities referred to in this report may not be suitable for all investors.

Investors should independently and carefully evaluate every particular investment and seek the advice of a financial adviser if needed.

The analysis contained in this research report is based on numerous assumptions; different assumptions could result in materially different results. Any valuations, projections and forecasts contained in this report are based on a number of assumptions and estimates and are subject to contingencies and uncertainties. The inclusion of any such valuations, projections and forecasts in this report should not be regarded as a representation or warranty by or on behalf of LHV or any person within LHV that such valuations, projections and forecasts or their underlying assumptions and estimates will be met or realised.

Past performance is not a reliable indicator of future returns.

Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate due to currency exchange rate moves and taxation considerations specific to that investor.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision.

The fair value range has been issued for a 12-18 month period and has been derived from a weighted approach combining both DCF valuation and relative multiple comparisons. The relative multiple comparisons further incorporate additional weighting considerations relating to the underlying metrics and time forecast periods. Company specific inputs have been forecast and a list of peer companies has been compiled by the LHV analyst(s) writing this research commentary, whereas the consensus peer data has been obtained from Bloomberg. For more detailed information about the valuation methods please contact the analyst(s) using the contact details provided above.

For a useful summary of our coverage of this company, including the current sensitivity analysis, please refer to our latest monthly product: The Baltic Equity Companion. Alternatively you can also contact the analyst(s) using the contact details provided above.

Although we do not issue explicit recommendations, for regulation compliance purposes we adhere to the following synthetic structure:

- Buy- Expected return of more than 10% within 12-18 months (including dividends)
- Neutral- Expected return from -5% to 10% within 12-18 months (including dividends)
- Sell- Expected return less than -5% within 12-18 months (including dividends)

In the 12-month period preceding 01.04.2020 LHV has issued recommendations, of which 39.3% have been 'Buy' recommendations, 44.0% as 'Neutral', 4.8% as 'Sell' and 11.9% as 'under review'. Of all the 'Buy' recommendations issued, 15.2% have been for companies for which LHV has provided investment banking services in the preceding 12-month period. Of all the 'Neutral' recommendations issued, 13.5% have been issued to companies for which LHV has provided investment banking services in the preceding 12-month period. The classification is based on the above structure.

For a list of recommendations that were disseminated during the preceding 12-month period, including the date of dissemination, the identity of the person(s) who produced the recommendation, the price target and the relevant market price at the time of dissemination, the direction of the recommendation and the validity time period of the price target, please contact the analyst(s) using the contact details provided above.

